^
Association details:
| Biomarker: | HOXA9 methylation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | veliparib (ABT-888) (PARP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients.
Published date:
05/16/2018
Excerpt:
Plasma from OC patients were retrieved at baseline before initiation of daily oral single agent Veliparib...Patients with methylated HOXA9 showed a worse progression-free survival (p = 0.046) compared to patients with non-methylated HOXA9….The data presented suggests circulating methylated HOXA9 as a potential marker for prediction of efficacy of PARPi treatment.
DOI:
10.1200/JCO.2018.36.15_suppl.5540
Trial ID:
